We specialize in fostering partnerships between innovative biotech companies in Korea and Europe.
Currently, we are collaborating with a leading Korean biotech company that has developed an advanced Dual CAR-T therapy, which we believe could offer significant value to your organization.
The key features of this innovative technology are as follows:
-
First CAR-T technology targeting solid tumors using a combination of a monobody (based on human fibronectin 3 scaffold) and scFv, which represents a major advancement in the treatment of solid tumors.
-
High binding specificity towards EphA2 and PD-L1 targets, ensuring precise action with minimal off-target effects, thus maximizing treatment efficacy.
-
Rapid dissociation, resulting in low side effects and enhanced patient safety, making this technology both effective and safer for patients.
